

بسم الله الرحمن الرحيم



SALWA AKL



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم



SALWA AKL

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



SALWA AKL



بعض الوثائق الأصلية تالفة



SALWA AKL



بالرسالة صفحات

لم ترد بالأصل



SALWA AKL

***"STABILITY INDICATING METHODS FOR
THE DETERMINATION OF SOME AMIDE
AND /OR AMINE CONTAINING
PHARMACEUTICALS"***

Thesis presented by

Nour EL-Deen Wageih Sayed

B.Pharm.Sci. Cairo University

(1996)

For Partial Fulfillment of the
Master Degree In Pharmaceutical Sciences

"Analytical Chemistry "

Under the supervision of

Prof.Dr. Badr E.El-Zeany

Professor of Analytical Chemistry

Faculty of Pharmacy

Cairo University

Prof.Dr. Mohamed A.El-Kawy

Professor of Analytical Chemistry

Faculty of Pharmacy

Cairo University

Dr. Nagiba Y. Hasan

Lecturer of Analytical Chemistry

Faculty of Pharmacy

Cairo University

2001

ACKNOWLEDGEMENT

First I feel always grateful to " ALLAH ", the kindest and the most merciful.

I am deeply grateful to **Prof.Dr. Badr E.El-Zeany**, Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo University for his kind supervision, valuable advise, continuous encouragement and guidance as well as his constructive comments and kind help during all stages of the thesis.

I like to thank **Prof.Dr. Mohamed A.El-Kawy**, Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo University for his beneficial discussions, continuous encouragement and valuable assistance throughout the whole work.

I am also deeply grateful to **Dr. Nagiba Y. Hasan**, Lecturer of Analytical Chemistry, Faculty of Pharmacy, Cairo University for her valuable assistance and continuous encouragement.

I am indebted profoundly to my mother and brother for their patience, understanding and effective support during the whole work.

Finally, I wish to express my appreciation and thanks to my colleagues in the Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Beni suef branch.

NOTE

Beside the work carried I this thesis, the candidate has attended and successfully passed the postgraduate courses examination with the grades mentioned in the following

Subject	Grade
Computer and its application	GOOD
Statistics	ACCEPTED
Quality control	EXCELLENT
Bioavailability	EXCELLENT
Stability indicating methods	EXCELLENT
Instrumental analysis	GOOD
Higher mathematics	GOOD
Searching the literature	VERY GOOD

LIST OF CONTENTS

PREFACE.....	I-II
---------------------	-------------

PART I: GENERAL INTRODUCTION

1.1. Concepts in drug stability	1
1.2. Sources of drugs degradation.....	1
1.3. Stability indicating methods of analysis.....	3

PART II: STABILITY INDICATING METHODS FOR THE DETERMINATION OF ACECLOFENAC

II.1.0 LITERATURE REVIEW.....	9
II.1.1 STRUCTURE.....	9
II.1.2 PROPERTIES.....	9
II.1.3 PHARMACOLOGY.....	9
II.1.4 METHODS OF ANALYSIS.....	10
II.2.0 EXPERIMENTAL STUDY.....	12
II.2.1.0.Samples, reagents and apparatus.....	12
II.2.2.0. Procedures.....	15
II.3.0. RESULTS AND DISCUSSION.....	24
II.3.1.Degradation of aceclofenac.....	24
II.3.2.Third derivative (D_3) spectrophotometric method..	28
II.3.3.Ratio-spectra first derivative (RSD_1) spectrophotometric method.....	32
II.3.4.pH-induced difference (ΔA) spectrophotometric method..	44
II.3.5. Densitometric method.....	49
II.3.6. HPLC method.....	55

II.3.7. Statistical analysis.....	62
-----------------------------------	----

PART III: STABILITY INDICATING METHODS FOR THE DETERMINATION OF CLOZAPINE

III.1.0 LITERATURE REVIEW.....	67
III.1.1 STRUCTURE.....	67
III.1.2 PROPERTIES.....	67
III.1.3 PHARMACOLOGY.....	67
III.1.4 METHODS OF ANALYSIS.....	68
III.2.0 EXPERIMENTAL STUDY.....	75
III.2.1.0. Samples, reagents and apparatus.....	75
III.2.2.0. Procedures.....	78
III.3.0. RESULTS AND DISCUSSION.....	86
III.3.1. Degradation of clozapine.....	86
III.3.2. Second (D ₂) and Third derivative (D ₃) spectrophotometric method	90
III.3.3. Ratio-spectra first derivative (RSD ₁) spectrophotometric method.....	98
III.3.4. pH-induced difference (ΔA) spectrophotometric method..	104
III.3.5. Densitometric method.....	111
III.3.6. HPLC method.....	117
III.3.7. Statistical analysis.....	124

PART IV: STABILITY INDICATING METHODS FOR THE DETERMINATION OF DILOXANIDE FUROATE

IV.1.0 LITERATURE REVIEW.....	130
IV.1.1 STRUCTURE.....	130

IV.1.2 PROPERTIES.....	130
IV.1.3 PHARMACOLOGY.....	130
IV.1.4 METHODS OF ANALYSIS.....	131
IV.2.0 EXPERIMENTAL STUDY.....	136
IV.2.1.0.Samples, reagents and apparatus.....	136
IV.2.2.0. Procedures.....	140
IV.3.0. RESULTS AND DISCUSSION.....	149
IV.3.1.Degradation of diloxanide furoate.....	149
IV.3.2.First(D_1) and Second (D_2) derivative (D_3)spectrophotometric method.....	153
IV.3.3.Ratio-spectra first derivative (RSD_1) spectrophotometric method.....	161
IV.3.4.pH-induced difference (ΔA) spectrophotometric method	167
IV.3.5. Densitometric method.....	174
IV.3.6. HPLC method.....	181
IV.3.7. Statistical analysis.....	187

LIST OF FIGURES

Figure (1): The proposed pathway of aceclofenac degradation.....	25
Figure (2): Thin layer chromatogram of reference standard aceclofenac and its degradation product using tetrahydrofuran: methanol (90:10 v/v) as mobile phase.....	26
Figure (3): IR spectra of intact aceclofenac and its degradation Product.....	27
Figure (4): Zero-order spectra of the ethanolic solutions of intact aceclofenac (30 µg/ml) and its degradation product (5 µg/ml).....	29
Figure (5): Third derivative spectra of the ethanolic solutions of intact aceclofenac (30 µg/ml) and its degradation product (5 µg/ml).....	30
Figure (6): Linearity of the peak heights of the third derivative spectra of intact aceclofenac at 242nm.....	31
Figure (7): Ratio-spectra & first derivative curves of the ethanolic solutions of intact aceclofenac (20µg/ml) using 5µg/ml of the degradation product as the divisor	38
Figure (8): Linearity of the peak amplitude at 245nm to the concentration of pure aceclofenac.....	39
Figure (9): Difference spectra of intact aceclofenac (15µg/ml) and its degradation product (5µg/ml).....	45
Figure (10): Linearity of the peak amplitude at 273nm to the concentration of aceclofenac.....	46

Figure (11): Scanning profile of a TLC chromatogram of aceclofenac.....	52
Figure (12): Linearity of the peak area to the concentration of pure aceclofenac.....	53
Figure (13): HPLC chromatograms of intact aceclofenac (20ug/ml) and its degradate (20ug/ml).....	59
Figure (14): Linearity of the peak area to the concentration of pure Aceclofenac.....	60
Figure (15): The proposed pathway of clozapine degradation.....	87
Figure (16): Thin layer chromatogram of reference standard clozapine degradation product using methanol: water (40:60 v/v) as mobile phase.....	88
Figure (17): IR spectra of intact aceclofenac and its degradation product.....	89
Figure (18): Zero-order spectra of intact clozapine (10 ug/ml) and its degradation product (3 ug/ml).....	91
Figure (19): Second derivative spectra of the methanolic solutions of intact clozapine (10 ug/ml) and its degradation product (3 ug/ml).....	92
Figure (20): Third derivative spectra of the methanolic solutions of intact clozapine (10 ug/ml) and its degradation product (3 ug/ml).....	93
Figure (21): Linearity of the peak heights of the second derivative spectra of intact clozapine at 315nm.....	94

Figure (22): Linearity of the peak heights of the third derivative spectra of intact clozapine at 305 nm.....	95
Figure (23): Ratio-spectra & first derivative curves of the ethanolic solutions of intact clozapine (10ug/ml) using 3ug/ml of the degradation product as the divisor....	101
Figure (24): Linearity of the peak amplitude at 295 nm to the concentration of pure clozapine.....	102
Figure (25): Difference spectra of intact clozapine (15 ug/ml) and its degradation product (5 ug/ml).....	108
Figure (26): Linearity of the peak amplitude at 325 nm to the concentration of pure clozapine.....	109
Figure (27): Scanning profile of a TLC chromatogram of clozapine.....	115
Figure (28): Linearity of the peak area to the concentration of pure clozapine.....	116
Figure (29): HPLC chromatograms of intact clozapine (20ug/ml) and its degradate (10ug/ml).....	122
Figure (30): Linearity of the peak area to the concentration of pure clozapine.....	123
Figure (31): The proposed pathway of diloxanide furoate degradation.....	150
Figure (32): Thin layer chromatogram of reference standard diloxanide furoate and its degradation products using chloroform: methanol (80:20 v/v) as mobile phase.....	151
Figure (33): IR spectra of intact diloxanide furoate and its degrada-	

tion products.....	152
Figure (34): Zero-order spectra of the methanolic solutions of intact diloxanide furoate (15 ug/ml), first degradation product (3 ug/ml) and second degradation product (3 ug/ml)...	154
Figure (35): First derivative spectra of the methanolic solutions of intact diloxanide furoate (15 ug/ml), first degradation product (3ug/ml) and second degradation product (3 ug/ ml).....	155
Figure (36): Second derivative spectra of the methanolic solutions of intact diloxanide furoate (15 ug/ml), first degradation product (3ug/ml) and second degradation product (3 ug/ ml).....	156
Figure (37): Linearity of the peak heights of the first derivative spectra of intact diloxanide furoate at 270 nm.....	157
Figure (38): Lincarity of the peak heights of the second derivative spectra of intact diloxanide furoate at 280 nm.....	158
Figure (39): Ratio-spectra & first derivative curves of the methanolic solutions of intact diloxanide furoate (10 ug/ml), first degradation product (3 ug/ml) using 3ug/ml of the second degradation product as the divisor.....	164
Figure (40): Linearity of the peak amplitude at 270 nm to the concen- tration of pure diloxanide furoate.....	165
Figure (41): Difference spectra of intact diloxanide furoate (20 ug/ml). first degradation product (5 ug/ml) and second degradation	